摘要
["PURPOSE: Age-related macular degeneration (AMD) can cause irreversible vision loss leading to blindness. We aim to evaluate the efficacy and safety of intravitreal injections of 0.5 mg conbercept, a new anti vascular endothelial growth factor (anti-VEGF) drug, for treatment of AMD on a schedule more manageable for patients.","DESIGN: A prospective, double-masked, multicenter, sham-controlled, phase III randomized trial.","METHODS: PATIENTS: Patients with choroidal neovascularization (CNV) secondary to AMD were enrolled and randomized to the conbercept group or the sham control group. INTERVENTION: The conbercept group received intravitreal injections of conbercept (0.5 mg) once monthly for the first 3 months, then once quarterly until month 12 (3 + Q3M). The sham group received first 3 monthly sham injections and then 3 monthly injections of conbercept (0.5 mg) followed by quarterly administrations until month 12. MAIN OUTCOME MEASURES: The primary endpoint was mean change from baseline in best-corrected visual acuity (BCVA) at month 3.","RESULTS: A total of 114 patients (91.9%) from 9 sites in China completed the 12-month study. At the 3-month primary endpoint, the mean changes in BCVA from baseline were + 9.20 letters in the conbercept group and + 2.02 letters in the sham group, respectively (P <.001). At 12 months, the mean changes from baseline in BCVA letter score were + 9.98 letters in the conbercept group and + 8.81 letters in the sham group (P =.64). The most common ocular adverse events were associated with intravitreal injections, such as conjunctival hemorrhage, and increased intraocular pressure.","CONCLUSIONS: A conbercept dosing regimen of 3 initial monthly administrations followed by quarterly treatments is effective for treatment of AMD. In previous reports, other anti-VEGF agents were unable to maintain similar clinical benefits with the same regimen. (C) 2018 Elsevier Inc. All rights reserved.)"]
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 156-167 |
| 页数 | 12 |
| 期刊 | American Journal of Ophthalmology |
| 卷 | 197 |
| DOI | |
| 出版状态 | 已出版 - 1月 2019 |
基金资助
THIS WORK WAS SUPPORTED BY CHENGDU KANGHONG BIOTECHNOLOGY INC (CHENGDU, SICHUAN, China). The sponsor participated in the design of the study, conducting the study, data collection, data management, and preparation of the manuscript. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
收录
- SCIE
学术指纹
探究 'Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 PHOENIX Study' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver